Heart-failure biotech Avery Therapeutics files for $15.4M raise
What's the deal? Avery TherapeuticsDealroom has a profile for this one. Try Dealroom →, a Tucson, Arizona biotechnology company, has filed a notice with the US Securities and Exchange Commission for an exempt securities offering to raise up to $15.4 million. The filing reports $8.47 million sold so far, with the first sale dated August 19, 2026. It does not name investors or confirm the full offering has closed.
What's the endgame? Avery develops immunomodulatory biologic therapeutics aimed at redirecting the immune system toward repair in diseases of aging, inflammation, and fibrosis. Its lead product, MyCardia, is a tissue-engineered heart graft in pre-clinical development, intended to restore cardiac function in patients with chronic heart failure.
Why now? The company, spun out of the University of Arizona's Sarver Heart Center, was founded in 2016 and employs fewer than 10 people. This is its first SEC Form D filing, making it a new filer rather than a repeat fundraiser.
What could go wrong? The notice offers little beyond the capital figures. Without details on use of proceeds, investors, or program milestones, the financing's significance is hard to assess. A tissue-engineered heart graft in pre-clinical stage also faces a long road to clinical testing.
The signal: Biotech showed selective momentum in the third quarter, with venture funding moderating even as public offerings improved. Investors have favored companies with clearer paths toward the clinic — a bar Avery's early-stage graft has yet to clear.
Read more: intelligence360.news
Image credit: Generated with Gemini
